{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:55:31Z","timestamp":1792032931253,"version":"4.4.0"},"reference-count":332,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82303435"],"award-info":[{"award-number":["No. 82303435"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["No. tsqn202312381"],"award-info":[{"award-number":["No. tsqn202312381"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["No. ZR2023QH213"],"award-info":[{"award-number":["No. ZR2023QH213"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["No. 2023KJ357"],"award-info":[{"award-number":["No. 2023KJ357"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02667-w","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:26:13Z","timestamp":1776853573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The RNA methylation modification as an immunometabolic regulatory hub in pancreatic cancer: from mechanistic insights to clinical translation perspectives"],"prefix":"10.1186","volume":"25","author":[{"given":"Yinghao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisheng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faxian","family":"Hei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"1","key":"2667_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2667_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2667_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102180","volume":"96","author":"S De Dosso","year":"2021","unstructured":"De Dosso S, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2667_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104528","volume":"10","author":"T Conroy","year":"2025","unstructured":"Conroy T, Ducreux M. ESMO clinical practice guideline express update on the management of metastatic pancreatic cancer. ESMO Open. 2025;10(4):104528.","journal-title":"ESMO Open"},{"issue":"10409","key":"2667_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"issue":"9","key":"2667_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362.","journal-title":"JAMA"},{"issue":"8","key":"2667_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","volume":"20","author":"X Deng","year":"2023","unstructured":"Deng X, et al. The roles and implications of RNA m(6)A modification in cancer. Nat Rev Clin Oncol. 2023;20(8):507\u201326.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2667_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, et al. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17(1):40.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2667_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-025-02265-0","volume":"10","author":"X Liu","year":"2025","unstructured":"Liu X, et al. Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis. Signal Transduct Target Ther. 2025;10(1):182.","journal-title":"Signal Transduct Target Ther"},{"key":"2667_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102261","volume":"52","author":"T Aziguli","year":"2025","unstructured":"Aziguli T, et al. ENO1 promotes PDAC progression by inhibiting CD8(+) T cell infiltration through upregulating PD-L1 expression via HIF-1\u03b1 signaling. Transl Oncol. 2025;52:102261.","journal-title":"Transl Oncol"},{"issue":"1","key":"2667_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","volume":"19","author":"C Qin","year":"2020","unstructured":"Qin C, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50.","journal-title":"Mol Cancer"},{"issue":"756","key":"2667_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi0178","volume":"16","author":"S Zheng","year":"2024","unstructured":"Zheng S, et al. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Sci Transl Med. 2024;16(756):eadi0178.","journal-title":"Sci Transl Med"},{"key":"2667_CR13","doi-asserted-by":"crossref","unstructured":"Zheng Q, et al. Genetic characteristics and prognostic implications of m1A regulators in pancreatic cancer. Biosci Rep. 2021;41(4).","DOI":"10.1042\/BSR20210337"},{"key":"2667_CR14","doi-asserted-by":"crossref","unstructured":"Lu J, et al. Identification of m7G-Related LncRNA Signature for Predicting Prognosis and Evaluating Tumor Immune Infiltration in Pancreatic Adenocarcinoma. Diagnostics (Basel). 2023;13(10).","DOI":"10.3390\/diagnostics13101697"},{"issue":"3","key":"2667_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285\u201395.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"2667_CR16","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s11427-024-2648-0","volume":"68","author":"Q Xiong","year":"2025","unstructured":"Xiong Q, et al. Regulation and application of m(6)A modification in tumor immunity. Sci China Life Sci. 2025;68(4):974\u201393.","journal-title":"Sci China Life Sci"},{"issue":"1","key":"2667_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2022.100075","volume":"2","author":"J Liu","year":"2023","unstructured":"Liu J, et al. Intertwined regulation between RNA m(6)A modification and cancer metabolism. Cell Insight. 2023;2(1):100075.","journal-title":"Cell Insight"},{"issue":"1","key":"2667_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00018-024-05573-w","volume":"82","author":"Z Bai","year":"2025","unstructured":"Bai Z, et al. N(6)-methylandenosine-related lncRNAs as potential biomarkers for predicting prognosis and the immunotherapy response in pancreatic cancer. Cell Mol Life Sci. 2025;82(1):48.","journal-title":"Cell Mol Life Sci"},{"issue":"D1","key":"2667_CR19","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, et al. Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53(D1):D1670-d1676.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2667_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/wrna.1144","volume":"4","author":"JE Jackman","year":"2013","unstructured":"Jackman JE, Alfonzo JD. Transfer RNA modifications: nature\u2019s combinatorial chemistry playground. Wiley Interdiscip Rev RNA. 2013;4(1):35\u201348.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"6","key":"2667_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41580-021-00342-0","volume":"22","author":"T Suzuki","year":"2021","unstructured":"Suzuki T. The expanding world of tRNA modifications and their disease relevance. Nat Rev Mol Cell Biol. 2021;22(6):375\u201392.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"2667_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, et al. Dynamic RNA Modifications in Gene Expression Regulation. Cell. 2017;169(7):1187\u2013200.","journal-title":"Cell"},{"issue":"2","key":"2667_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41576-023-00645-2","volume":"25","author":"S Delaunay","year":"2024","unstructured":"Delaunay S, Helm M, Frye M. RNA modifications in physiology and disease: towards clinical applications. Nat Rev Genet. 2024;25(2):104\u201322.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"2667_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1586","volume":"11","author":"JD Jones","year":"2020","unstructured":"Jones JD, Monroe J, Koutmou KS. A molecular-level perspective on the frequency, distribution, and consequences of messenger RNA modifications. Wiley Interdiscip Rev RNA. 2020;11(4):e1586.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"1","key":"2667_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/acs.accounts.3c00532","volume":"57","author":"LS Zhang","year":"2024","unstructured":"Zhang LS, Dai Q, He C. Base-resolution sequencing methods for whole-transcriptome quantification of mRNA modifications. Acc Chem Res. 2024;57(1):47\u201358.","journal-title":"Acc Chem Res"},{"issue":"3","key":"2667_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41587-022-01487-9","volume":"41","author":"C Liu","year":"2023","unstructured":"Liu C, et al. Absolute quantification of single-base m(6)A methylation in the mammalian transcriptome using GLORI. Nat Biotechnol. 2023;41(3):355\u201366.","journal-title":"Nat Biotechnol"},{"key":"2667_CR27","doi-asserted-by":"crossref","unstructured":"Tian L, Vallabhaneni B, Chang YH. Advances in Quantitative Techniques for Mapping RNA Modifications. Life (Basel). 2025;15(12).","DOI":"10.3390\/life15121888"},{"issue":"1","key":"2667_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ccell.2025.12.001","volume":"44","author":"X Deng","year":"2026","unstructured":"Deng X, et al. Epitranscriptomic control of cancer hallmarks: functions, mechanisms, and therapeutics of RNA modifications. Cancer Cell. 2026;44(1):50\u201376.","journal-title":"Cancer Cell"},{"issue":"5","key":"2667_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nchembio.2040","volume":"12","author":"X Li","year":"2016","unstructured":"Li X, et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat Chem Biol. 2016;12(5):311\u20136.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2667_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s43587-023-00556-1","volume":"4","author":"H He","year":"2024","unstructured":"He H, et al. Age-related noncanonical TRMT6-TRMT61A signaling impairs hematopoietic stem cells. Nat Aging. 2024;4(2):213\u201330.","journal-title":"Nat Aging"},{"issue":"5","key":"2667_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/cbic.201500013","volume":"16","author":"SM Huber","year":"2015","unstructured":"Huber SM, et al. Formation and abundance of 5-hydroxymethylcytosine in RNA. ChemBioChem. 2015;16(5):752\u20135.","journal-title":"ChemBioChem"},{"issue":"6","key":"2667_CR32","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.molcel.2019.03.036","volume":"74","author":"LS Zhang","year":"2019","unstructured":"Zhang LS, et al. Transcriptome-wide Mapping of Internal N(7)-Methylguanosine Methylome in Mammalian mRNA. Mol Cell. 2019;74(6):1304-1316.e8.","journal-title":"Mol Cell"},{"issue":"10","key":"2667_CR33","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41580-023-00622-x","volume":"24","author":"H Sun","year":"2023","unstructured":"Sun H, et al. Regulation and functions of non-m(6)A mRNA modifications. Nat Rev Mol Cell Biol. 2023;24(10):714\u201331.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"2667_CR34","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1021\/acschembio.2c00792","volume":"17","author":"LS Zhang","year":"2022","unstructured":"Zhang LS, et al. m(7)G-quant-seq: quantitative detection of RNA internal N(7)-methylguanosine. ACS Chem Biol. 2022;17(12):3306\u201312.","journal-title":"ACS Chem Biol"},{"issue":"7","key":"2667_CR35","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.cell.2012.05.003","volume":"149","author":"KD Meyer","year":"2012","unstructured":"Meyer KD, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3\u2019 UTRs and near stop codons. Cell. 2012;149(7):1635\u201346.","journal-title":"Cell"},{"issue":"4","key":"2667_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1261\/rna.080324.124","volume":"31","author":"S Stejskal","year":"2025","unstructured":"Stejskal S, et al. Global analysis by LC-MS\/MS of N6-methyladenosine and inosine in mRNA reveal complex incidence. RNA. 2025;31(4):514\u201328.","journal-title":"RNA"},{"issue":"1","key":"2667_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tips.2023.11.002","volume":"45","author":"J Cerneckis","year":"2024","unstructured":"Cerneckis J, et al. The rise of epitranscriptomics: recent developments and future directions. Trends Pharmacol Sci. 2024;45(1):24\u201338.","journal-title":"Trends Pharmacol Sci"},{"issue":"7679","key":"2667_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature24456","volume":"551","author":"M Safra","year":"2017","unstructured":"Safra M, et al. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017;551(7679):251\u20135.","journal-title":"Nature"},{"issue":"12","key":"2667_CR39","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41423-022-00942-6","volume":"19","author":"C Chen","year":"2022","unstructured":"Chen C, Ye L. The m1A modification of tRNAs: a translational accelerator of T-cell activation. Cell Mol Immunol. 2022;19(12):1328\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"2667_CR40","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41592-019-0550-4","volume":"16","author":"H Zhou","year":"2019","unstructured":"Zhou H, et al. Evolution of a reverse transcriptase to map N(1)-methyladenosine in human messenger RNA. Nat Methods. 2019;16(12):1281\u20138.","journal-title":"Nat Methods"},{"key":"2667_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/0006-3002(61)90668-0","volume":"46","author":"DB Dunn","year":"1961","unstructured":"Dunn DB. The occurrence of 1-methyladenine in ribonucleic acid. Biochim Biophys Acta. 1961;46:198\u2013200.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2667_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41420-023-01458-2","volume":"9","author":"Z Qi","year":"2023","unstructured":"Qi Z, et al. N(1)-methyladenosine modification of mRNA regulates neuronal gene expression and oxygen glucose deprivation\/reoxygenation induction. Cell Death Discov. 2023;9(1):159.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2667_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12964-023-01401-z","volume":"22","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Research progress of N1-methyladenosine RNA modification in cancer. Cell Commun Signal. 2024;22(1):79.","journal-title":"Cell Commun Signal"},{"issue":"44","key":"2667_CR44","doi-asserted-by":"publisher","first-page":"13382","DOI":"10.1021\/ja075520+","volume":"129","author":"F Voigts-Hoffmann","year":"2007","unstructured":"Voigts-Hoffmann F, et al. A methyl group controls conformational equilibrium in human mitochondrial tRNA(Lys). J Am Chem Soc. 2007;129(44):13382\u20133.","journal-title":"J Am Chem Soc"},{"issue":"20","key":"2667_CR45","first-page":"11126","volume":"46","author":"E Vilardo","year":"2018","unstructured":"Vilardo E, et al. A subcomplex of human mitochondrial RNase P is a bifunctional methyltransferase - extensive moonlighting in mitochondrial tRNA biogenesis. Nucleic Acids Res. 2018;46(20):11126\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2667_CR46","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41556-021-00709-7","volume":"23","author":"LS Zhang","year":"2021","unstructured":"Zhang LS, et al. ALKBH7-mediated demethylation regulates mitochondrial polycistronic RNA processing. Nat Cell Biol. 2021;23(7):684\u201391.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"2667_CR47","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1261\/rna.035600.112","volume":"18","author":"T Chujo","year":"2012","unstructured":"Chujo T, Suzuki T. Trmt61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial tRNAs. RNA. 2012;18(12):2269\u201376.","journal-title":"RNA"},{"key":"2667_CR48","doi-asserted-by":"publisher","first-page":"32562","DOI":"10.1038\/srep32562","volume":"6","author":"M Wang","year":"2016","unstructured":"Wang M, et al. Crystal structure of the two-subunit tRNA m(1)A58 methyltransferase TRM6-TRM61 from Saccharomyces cerevisiae. Sci Rep. 2016;6:32562.","journal-title":"Sci Rep"},{"issue":"9","key":"2667_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002557","volume":"14","author":"D Bar-Yaacov","year":"2016","unstructured":"Bar-Yaacov D, et al. Mitochondrial 16S rRNA Is Methylated by tRNA Methyltransferase TRMT61B in All Vertebrates. PLoS Biol. 2016;14(9):e1002557.","journal-title":"PLoS Biol"},{"issue":"12","key":"2667_CR50","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1242\/jcs.183723","volume":"129","author":"T Waku","year":"2016","unstructured":"Waku T, et al. NML-mediated rRNA base methylation links ribosomal subunit formation to cell proliferation in a p53-dependent manner. J Cell Sci. 2016;129(12):2382\u201393.","journal-title":"J Cell Sci"},{"issue":"7","key":"2667_CR51","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.cell.2016.11.045","volume":"167","author":"F Liu","year":"2016","unstructured":"Liu F, et al. ALKBH1-mediated tRNA demethylation regulates translation. Cell. 2016;167(7):1897.","journal-title":"Cell"},{"issue":"5","key":"2667_CR52","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1093\/nar\/gky1250","volume":"47","author":"Z Chen","year":"2019","unstructured":"Chen Z, et al. Transfer RNA demethylase ALKBH3 promotes cancer progression via induction of tRNA-derived small RNAs. Nucleic Acids Res. 2019;47(5):2533\u201345.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2667_CR53","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.molcel.2018.08.011","volume":"71","author":"J Wei","year":"2018","unstructured":"Wei J, et al. Differential m(6)A, m(6)A(m), and m(1)A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell. 2018;71(6):973-985.e5.","journal-title":"Mol Cell"},{"key":"2667_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.883155","volume":"9","author":"Y Wu","year":"2022","unstructured":"Wu Y, et al. N1-Methyladenosine (m1A) Regulation Associated With the Pathogenesis of Abdominal Aortic Aneurysm Through YTHDF3 Modulating Macrophage Polarization. Front Cardiovasc Med. 2022;9:883155.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"2667_CR55","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1021\/acs.analchem.8b01703","volume":"90","author":"X Dai","year":"2018","unstructured":"Dai X, et al. Identification of YTH domain-containing proteins as the readers for N1-methyladenosine in RNA. Anal Chem. 2018;90(11):6380\u20134.","journal-title":"Anal Chem"},{"issue":"7591","key":"2667_CR56","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nature16998","volume":"530","author":"D Dominissini","year":"2016","unstructured":"Dominissini D, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016;530(7591):441\u20136.","journal-title":"Nature"},{"issue":"9","key":"2667_CR57","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.3270","volume":"23","author":"H Zhou","year":"2016","unstructured":"Zhou H, et al. m(1)A and m(1)G disrupt A-RNA structure through the intrinsic instability of Hoogsteen base pairs. Nat Struct Mol Biol. 2016;23(9):803\u201310.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"2667_CR58","doi-asserted-by":"publisher","first-page":"11904","DOI":"10.1038\/s41598-018-30383-z","volume":"8","author":"S Sharma","year":"2018","unstructured":"Sharma S, et al. A single N(1)-methyladenosine on the large ribosomal subunit rRNA impacts locally its structure and the translation of key metabolic enzymes. Sci Rep. 2018;8(1):11904.","journal-title":"Sci Rep"},{"issue":"8","key":"2667_CR59","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41556-019-0361-y","volume":"21","author":"X Chen","year":"2019","unstructured":"Chen X, et al. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019;21(8):978\u201390.","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2667_CR60","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1093\/nar\/gkae110","volume":"52","author":"T Zhang","year":"2024","unstructured":"Zhang T, et al. Programmable RNA 5-methylcytosine (m5C) modification of cellular RNAs by dCasRx conjugated methyltransferase and demethylase. Nucleic Acids Res. 2024;52(6):2776\u201391.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2667_CR61","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/nar\/gkaa1193","volume":"49","author":"T Selmi","year":"2021","unstructured":"Selmi T, et al. Sequence- and structure-specific cytosine-5 mRNA methylation by NSUN6. Nucleic Acids Res. 2021;49(2):1006\u201322.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2667_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12915-020-00769-5","volume":"18","author":"U Schumann","year":"2020","unstructured":"Schumann U, et al. Multiple links between 5-methylcytosine content of mRNA and translation. BMC Biol. 2020;18(1):40.","journal-title":"BMC Biol"},{"issue":"5","key":"2667_CR63","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/cr.2017.55","volume":"27","author":"X Yang","year":"2017","unstructured":"Yang X, et al. 5-methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m(5)C reader. Cell Res. 2017;27(5):606\u201325.","journal-title":"Cell Res"},{"key":"2667_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/genes10020102","author":"KE Bohnsack","year":"2019","unstructured":"Bohnsack KE, H\u00f6bartner C, Bohnsack MT. Eukaryotic 5-methylcytosine (m5C) RNA methyltransferases: mechanisms, cellular functions, and links to disease. Genes. 2019. https:\/\/doi.org\/10.3390\/genes10020102.","journal-title":"Genes"},{"issue":"6","key":"2667_CR65","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.molcel.2019.06.033","volume":"75","author":"Y Yang","year":"2019","unstructured":"Yang Y, et al. RNA 5-Methylcytosine Facilitates the Maternal-to-Zygotic Transition by Preventing Maternal mRNA Decay. Mol Cell. 2019;75(6):1188-1202.e11.","journal-title":"Mol Cell"},{"issue":"1","key":"2667_CR66","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1038\/s41467-022-30210-0","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Developmental mRNA m(5)C landscape and regulatory innovations of massive m(5)C modification of maternal mRNAs in animals. Nat Commun. 2022;13(1):2484.","journal-title":"Nat Commun"},{"issue":"19","key":"2667_CR67","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1093\/nar\/gkt679","volume":"41","author":"S Sharma","year":"2013","unstructured":"Sharma S, et al. Yeast Nop2 and Rcm1 methylate C2870 and C2278 of the 25S rRNA, respectively. Nucleic Acids Res. 2013;41(19):9062\u201376.","journal-title":"Nucleic Acids Res"},{"key":"2667_CR68","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1038\/ncomms7158","volume":"6","author":"M Schosserer","year":"2015","unstructured":"Schosserer M, et al. Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat Commun. 2015;6:6158.","journal-title":"Nat Commun"},{"issue":"20","key":"2667_CR69","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1093\/nar\/gkl765","volume":"34","author":"B Brzezicha","year":"2006","unstructured":"Brzezicha B, et al. Identification of human tRNA:m5C methyltransferase catalysing intron-dependent m5C formation in the first position of the anticodon of the pre-tRNA Leu (CAA). Nucleic Acids Res. 2006;34(20):6034\u201343.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2667_CR70","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.4161\/rna.22180","volume":"9","author":"S Auxilien","year":"2012","unstructured":"Auxilien S, et al. The human tRNA m (5) C methyltransferase Misu is multisite-specific. RNA Biol. 2012;9(11):1331\u20138.","journal-title":"RNA Biol"},{"issue":"6","key":"2667_CR71","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/wrna.1380","volume":"7","author":"W Wang","year":"2016","unstructured":"Wang W. mRNA methylation by NSUN2 in cell proliferation. Wiley Interdiscip Rev RNA. 2016;7(6):838\u201342.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"9","key":"2667_CR72","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1261\/rna.051524.115","volume":"21","author":"S Haag","year":"2015","unstructured":"Haag S, et al. NSUN6 is a human RNA methyltransferase that catalyzes formation of m5C72 in specific tRNAs. RNA. 2015;21(9):1532\u201343.","journal-title":"RNA"},{"issue":"5759","key":"2667_CR73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.1120976","volume":"311","author":"MG Goll","year":"2006","unstructured":"Goll MG, et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science. 2006;311(5759):395\u20138.","journal-title":"Science"},{"issue":"9","key":"2667_CR74","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1080\/15476286.2016.1191737","volume":"14","author":"A Jeltsch","year":"2017","unstructured":"Jeltsch A, et al. Mechanism and biological role of Dnmt2 in nucleic acid methylation. RNA Biol. 2017;14(9):1108\u201323.","journal-title":"RNA Biol"},{"issue":"7","key":"2667_CR75","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nchembio.2099","volume":"12","author":"S Nakano","year":"2016","unstructured":"Nakano S, et al. NSUN3 methylase initiates 5-formylcytidine biogenesis in human mitochondrial tRNA(Met). Nat Chem Biol. 2016;12(7):546\u201351.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2667_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004110","volume":"10","author":"MD Metodiev","year":"2014","unstructured":"Metodiev MD, et al. NSUN4 is a dual function mitochondrial protein required for both methylation of 12S rRNA and coordination of mitoribosomal assembly. PLoS Genet. 2014;10(2):e1004110.","journal-title":"PLoS Genet"},{"issue":"5","key":"2667_CR77","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cmet.2011.04.002","volume":"13","author":"Y C\u00e1mara","year":"2011","unstructured":"C\u00e1mara Y, et al. MTERF4 regulates translation by targeting the methyltransferase NSUN4 to the mammalian mitochondrial ribosome. Cell Metab. 2011;13(5):527\u201339.","journal-title":"Cell Metab"},{"issue":"1","key":"2667_CR78","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-020-01263-w","volume":"20","author":"P Nombela","year":"2021","unstructured":"Nombela P, Miguel-L\u00f3pez B, Blanco S. The role of m(6)A, m(5)C and \u03a8 RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer. 2021;20(1):18.","journal-title":"Mol Cancer"},{"issue":"1","key":"2667_CR79","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-immunol-080223-044610","volume":"42","author":"IF L\u00f3pez-Moyado","year":"2024","unstructured":"L\u00f3pez-Moyado IF, et al. TET Enzymes in the Immune System: From DNA Demethylation to Immunotherapy, Inflammation, and Cancer. Annu Rev Immunol. 2024;42(1):455\u201388.","journal-title":"Annu Rev Immunol"},{"issue":"33","key":"2667_CR80","doi-asserted-by":"publisher","first-page":"11582","DOI":"10.1021\/ja505305z","volume":"136","author":"L Fu","year":"2014","unstructured":"Fu L, et al. Tet-mediated formation of 5-hydroxymethylcytosine in RNA. J Am Chem Soc. 2014;136(33):11582\u20135.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2667_CR81","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1038\/s41467-022-31876-2","volume":"13","author":"AE Arguello","year":"2022","unstructured":"Arguello AE, et al. Reactivity-dependent profiling of RNA 5-methylcytidine dioxygenases. Nat Commun. 2022;13(1):4176.","journal-title":"Nat Commun"},{"issue":"12","key":"2667_CR82","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1093\/nar\/gkx354","volume":"45","author":"L Kawarada","year":"2017","unstructured":"Kawarada L, et al. ALKBH1 is an RNA dioxygenase responsible for cytoplasmic and mitochondrial tRNA modifications. Nucleic Acids Res. 2017;45(12):7401\u201315.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"2667_CR83","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/cr.2017.73","volume":"27","author":"D Dominissini","year":"2017","unstructured":"Dominissini D, Rechavi G. 5-methylcytosine mediates nuclear export of mRNA. Cell Res. 2017;27(6):717\u20139.","journal-title":"Cell Res"},{"issue":"12","key":"2667_CR84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116251119","volume":"119","author":"H Yang","year":"2022","unstructured":"Yang H, et al. FMRP promotes transcription-coupled homologous recombination via facilitating TET1-mediated m5C RNA modification demethylation. Proc Natl Acad Sci U S A. 2022;119(12):e2116251119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2667_CR85","doi-asserted-by":"crossref","unstructured":"Zeng Q, et al. Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion. Science. 2022;378(6621): eabl7207.","DOI":"10.1126\/science.abl7207"},{"issue":"23","key":"2667_CR86","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1016\/j.molcel.2023.10.028","volume":"83","author":"Z Zou","year":"2023","unstructured":"Zou Z, et al. FMRP phosphorylation modulates neuronal translation through YTHDF1. Mol Cell. 2023;83(23):4304-4317.e8.","journal-title":"Mol Cell"},{"issue":"1","key":"2667_CR87","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1021\/acs.analchem.9b04505","volume":"92","author":"X Dai","year":"2020","unstructured":"Dai X, et al. YTHDF2 binds to 5-methylcytosine in RNA and modulates the maturation of ribosomal RNA. Anal Chem. 2020;92(1):1346\u201354.","journal-title":"Anal Chem"},{"issue":"1","key":"2667_CR88","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-022-00362-8","volume":"10","author":"H Song","year":"2022","unstructured":"Song H, et al. Biological roles of RNA m(5)C modification and its implications in cancer immunotherapy. Biomark Res. 2022;10(1):15.","journal-title":"Biomark Res"},{"key":"2667_CR89","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/ncomms1692","volume":"3","author":"X Zhang","year":"2012","unstructured":"Zhang X, et al. The tRNA methyltransferase NSun2 stabilizes p16INK4 mRNA by methylating the 3\u2019-untranslated region of p16. Nat Commun. 2012;3:712.","journal-title":"Nat Commun"},{"issue":"15","key":"2667_CR90","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1016\/j.molcel.2022.06.022","volume":"82","author":"D Arango","year":"2022","unstructured":"Arango D, et al. Direct epitranscriptomic regulation of mammalian translation initiation through N4-acetylcytidine. Mol Cell. 2022;82(15):2912.","journal-title":"Mol Cell"},{"issue":"16","key":"2667_CR91","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511\u201326.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2667_CR92","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbagrm.2018.09.011","volume":"1862","author":"A Galloway","year":"2019","unstructured":"Galloway A, Cowling VH. mRNA cap regulation in mammalian cell function and fate. Biochim Biophys Acta Gene Regul Mech. 2019;1862(3):270\u20139.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"2667_CR93","doi-asserted-by":"crossref","unstructured":"Mars JC, et al. The Cap-Binding Complex CBC and the Eukaryotic Translation Factor eIF4E: Co-Conspirators in Cap-Dependent RNA Maturation and Translation. Cancers (Basel). 2021;13(24).","DOI":"10.3390\/cancers13246185"},{"key":"2667_CR94","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.omtn.2023.01.003","volume":"31","author":"X Xia","year":"2023","unstructured":"Xia X, Wang Y, Zheng JC. Internal m7G methylation: a novel epitranscriptomic contributor in brain development and diseases. Mol Ther Nucleic Acids. 2023;31:295\u2013308.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"2667_CR95","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1261\/rna.2030705","volume":"11","author":"A Alexandrov","year":"2005","unstructured":"Alexandrov A, Grayhack EJ, Phizicky EM. tRNA m7G methyltransferase Trm8p\/Trm82p: evidence linking activity to a growth phenotype and implicating Trm82p in maintaining levels of active Trm8p. RNA. 2005;11(5):821\u201330.","journal-title":"RNA"},{"issue":"2","key":"2667_CR96","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.molcel.2018.06.001","volume":"71","author":"S Lin","year":"2018","unstructured":"Lin S, et al. Mettl1\/Wdr4-Mediated m(7)G tRNA Methylome Is Required for Normal mRNA Translation and Embryonic Stem Cell Self-Renewal and Differentiation. Mol Cell. 2018;71(2):244-255.e5.","journal-title":"Mol Cell"},{"issue":"6","key":"2667_CR97","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.molcel.2019.03.040","volume":"74","author":"L Pandolfini","year":"2019","unstructured":"Pandolfini L, et al. METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation. Mol Cell. 2019;74(6):1278-1290.e9.","journal-title":"Mol Cell"},{"key":"2667_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.642080","volume":"9","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, et al. M7G methyltransferase METTL1 promotes post-ischemic angiogenesis via promoting VEGFA mRNA translation. Front Cell Dev Biol. 2021;9:642080.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"2667_CR99","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1093\/nar\/gkab465","volume":"49","author":"A Galloway","year":"2021","unstructured":"Galloway A, et al. Upregulation of RNA cap methyltransferase RNMT drives ribosome biogenesis during T cell activation. Nucleic Acids Res. 2021;49(12):6722\u201338.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2667_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167451","volume":"434","author":"MJ Osborne","year":"2022","unstructured":"Osborne MJ, et al. Identification and Characterization of the Interaction Between the Methyl-7-Guanosine Cap Maturation Enzyme RNMT and the Cap-Binding Protein eIF4E. J Mol Biol. 2022;434(5):167451.","journal-title":"J Mol Biol"},{"issue":"43","key":"2667_CR101","doi-asserted-by":"publisher","first-page":"26773","DOI":"10.1073\/pnas.2002360117","volume":"117","author":"B Culjkovic-Kraljacic","year":"2020","unstructured":"Culjkovic-Kraljacic B, et al. The eukaryotic translation initiation factor eIF4E elevates steady-state m(7)G capping of coding and noncoding transcripts. Proc Natl Acad Sci U S A. 2020;117(43):26773\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2667_CR102","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1261\/rna.047910.114","volume":"21","author":"S Haag","year":"2015","unstructured":"Haag S, Kretschmer J, Bohnsack MT. WBSCR22\/Merm1 is required for late nuclear pre-ribosomal RNA processing and mediates N7-methylation of G1639 in human 18S rRNA. RNA. 2015;21(2):180\u20137.","journal-title":"RNA"},{"issue":"12","key":"2667_CR103","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1093\/nar\/gkp249","volume":"37","author":"T Monecke","year":"2009","unstructured":"Monecke T, Dickmanns A, Ficner R. Structural basis for m7G-cap hypermethylation of small nuclear, small nucleolar and telomerase RNA by the dimethyltransferase TGS1. Nucleic Acids Res. 2009;37(12):3865\u201377.","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"2667_CR104","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1016\/j.cell.2023.05.047","volume":"186","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, et al. QKI shuttles internal m(7)G-modified transcripts into stress granules and modulates mRNA metabolism. Cell. 2023;186(15):3208-3226.e27.","journal-title":"Cell"},{"issue":"20","key":"2667_CR105","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz736","volume":"47","author":"C Enroth","year":"2019","unstructured":"Enroth C, et al. Detection of internal N7-methylguanosine (m7G) RNA modifications by mutational profiling sequencing. Nucleic Acids Res. 2019;47(20):e126.","journal-title":"Nucleic Acids Res"},{"key":"2667_CR106","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.omtn.2019.08.022","volume":"18","author":"W Chen","year":"2019","unstructured":"Chen W, et al. iRNA-m7G: identifying N(7)-methylguanosine sites by fusing multiple features. Mol Ther Nucleic Acids. 2019;18:269\u201374.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"2667_CR107","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. M(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37(3):270\u201388.","journal-title":"Cancer Cell"},{"issue":"10","key":"2667_CR108","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2667_CR109","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41420-024-02092-2","volume":"10","author":"X Han","year":"2024","unstructured":"Han X, et al. Progression of m(6)A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming. Cell Death Discov. 2024;10(1):331.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2667_CR110","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-022-01704-8","volume":"22","author":"X Cao","year":"2023","unstructured":"Cao X, et al. m(6)A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion. Mol Cancer. 2023;22(1):42.","journal-title":"Mol Cancer"},{"issue":"1","key":"2667_CR111","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-023-01477-7","volume":"16","author":"YN Qi","year":"2023","unstructured":"Qi YN, et al. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. J Hematol Oncol. 2023;16(1):89.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2667_CR112","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41419-022-05268-9","volume":"13","author":"Q Huang","year":"2022","unstructured":"Huang Q, et al. The RNA m(6)A writer WTAP in diseases: structure, roles, and mechanisms. Cell Death Dis. 2022;13(10):852.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2667_CR113","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41422-022-00725-8","volume":"32","author":"S Su","year":"2022","unstructured":"Su S, et al. Cryo-EM structures of human m(6)A writer complexes. Cell Res. 2022;32(11):982\u201394.","journal-title":"Cell Res"},{"issue":"8","key":"2667_CR114","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1073\/pnas.1820574116","volume":"116","author":"X Zhang","year":"2019","unstructured":"Zhang X, et al. Structural insights into FTO\u2019s catalytic mechanism for the demethylation of multiple RNA substrates. Proc Natl Acad Sci U S A. 2019;116(8):2919\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2667_CR115","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13578-024-01286-6","volume":"14","author":"Z Gao","year":"2024","unstructured":"Gao Z, et al. Insights into the m(6)A demethylases FTO and ALKBH5: structural, biological function, and inhibitor development. Cell Biosci. 2024;14(1):108.","journal-title":"Cell Biosci"},{"issue":"2","key":"2667_CR116","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.gpb.2018.04.002","volume":"16","author":"S Liao","year":"2018","unstructured":"Liao S, Sun H, Xu C. YTH Domain: A Family of N(6)-methyladenosine (m(6)A) Readers. Genomics Proteomics Bioinformatics. 2018;16(2):99\u2013107.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"2667_CR117","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tig.2016.03.006","volume":"32","author":"IA Roundtree","year":"2016","unstructured":"Roundtree IA, He C. Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Trends Genet. 2016;32(6):320\u20131.","journal-title":"Trends Genet"},{"issue":"2","key":"2667_CR118","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.molcel.2017.09.021","volume":"68","author":"MN Wojtas","year":"2017","unstructured":"Wojtas MN, et al. Regulation of m(6)A Transcripts by the 3\u2019\u21925\u2019 RNA Helicase YTHDC2 Is Essential for a Successful Meiotic Program in the Mammalian Germline. Mol Cell. 2017;68(2):374-387.e12.","journal-title":"Mol Cell"},{"issue":"7540","key":"2667_CR119","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nature14234","volume":"518","author":"N Liu","year":"2015","unstructured":"Liu N, et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015;518(7540):560\u20134.","journal-title":"Nature"},{"issue":"3","key":"2667_CR120","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.7150\/ijbs.104407","volume":"21","author":"ZH Liu","year":"2025","unstructured":"Liu ZH, et al. The mechanism and latest progress of m6A methylation in the progression of pancreatic cancer. Int J Biol Sci. 2025;21(3):1187\u2013201.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2667_CR121","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-023-01810-1","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Epigenetic modification of m(6)A regulator proteins in cancer. Mol Cancer. 2023;22(1):102.","journal-title":"Mol Cancer"},{"issue":"7","key":"2667_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167304","volume":"1870","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Identification of m6A modification patterns and RBM15 mediated macrophage phagocytosis in pancreatic cancer: An integrative analysis. Biochim Biophys Acta Mol Basis Dis. 2024;1870(7):167304.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2667_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216222","volume":"565","author":"J Chen","year":"2023","unstructured":"Chen J, et al. METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner. Cancer Lett. 2023;565:216222.","journal-title":"Cancer Lett"},{"key":"2667_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110440","volume":"99","author":"Y Tang","year":"2022","unstructured":"Tang Y, et al. METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5. Cell Signal. 2022;99:110440.","journal-title":"Cell Signal"},{"issue":"3","key":"2667_CR125","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41419-023-05715-1","volume":"14","author":"C Lin","year":"2023","unstructured":"Lin C, et al. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Cell Death Dis. 2023;14(3):221.","journal-title":"Cell Death Dis"},{"key":"2667_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101583","volume":"27","author":"Y He","year":"2023","unstructured":"He Y, et al. Linc-UROD stabilizes ENO1 and PKM to strengthen glycolysis, proliferation and migration of pancreatic cancer cells. Transl Oncol. 2023;27:101583.","journal-title":"Transl Oncol"},{"issue":"12","key":"2667_CR127","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41588-023-01568-8","volume":"55","author":"R Li","year":"2023","unstructured":"Li R, et al. Super-enhancer RNA m(6)A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Nat Genet. 2023;55(12):2224\u201334.","journal-title":"Nat Genet"},{"issue":"1","key":"2667_CR128","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41419-024-06425-y","volume":"15","author":"K Chen","year":"2024","unstructured":"Chen K, et al. FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Cell Death Dis. 2024;15(1):37.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2667_CR129","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-020-01249-8","volume":"19","author":"M Wang","year":"2020","unstructured":"Wang M, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N(6) adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol Cancer. 2020;19(1):130.","journal-title":"Mol Cancer"},{"issue":"1","key":"2667_CR130","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-021-01072-8","volume":"14","author":"S Chen","year":"2021","unstructured":"Chen S, et al. CLK1\/SRSF5 pathway induces aberrant exon skipping of METTL14 and cyclin L2 and promotes growth and metastasis of pancreatic cancer. J Hematol Oncol. 2021;14(1):60.","journal-title":"J Hematol Oncol"},{"issue":"37","key":"2667_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504064","volume":"12","author":"K Xu","year":"2025","unstructured":"Xu K, et al. Pancreatic cancer-derived extracellular vesicles enriched with miR-223-5p promote skeletal muscle wasting associated with cachexia. Adv Sci (Weinh). 2025;12(37):e04064.","journal-title":"Adv Sci (Weinh)"},{"key":"2667_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102176","volume":"34","author":"D Wu","year":"2025","unstructured":"Wu D, et al. 3D printing-biomimetic local stiff niche enhances glycolysis to boost PDAC cell stem-like phenotype via N6-methyladenosine-suppressed YAP1 mRNA decay. Mater Today Bio. 2025;34:102176.","journal-title":"Mater Today Bio"},{"issue":"12","key":"2667_CR133","doi-asserted-by":"publisher","first-page":"7701","DOI":"10.1097\/JS9.0000000000002116","volume":"110","author":"T Yi","year":"2024","unstructured":"Yi T, et al. METTL16 inhibits pancreatic cancer proliferation and metastasis by promoting MROH8 RNA stability and inhibiting CAPN2 expression - experimental studies. Int J Surg. 2024;110(12):7701\u201319.","journal-title":"Int J Surg"},{"key":"2667_CR134","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.canlet.2022.01.013","volume":"530","author":"C Huang","year":"2022","unstructured":"Huang C, et al. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Cancer Lett. 2022;530:16\u201328.","journal-title":"Cancer Lett"},{"issue":"16","key":"2667_CR135","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41388-025-03283-6","volume":"44","author":"L Gao","year":"2025","unstructured":"Gao L, et al. Alcohol-induced C\/EBP \u03b2-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A\/YTHDF2\/SLC43A2 pathway. Oncogene. 2025;44(16):1118\u201332.","journal-title":"Oncogene"},{"issue":"1","key":"2667_CR136","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-020-01158-w","volume":"19","author":"X Guo","year":"2020","unstructured":"Guo X, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Mol Cancer. 2020;19(1):91.","journal-title":"Mol Cancer"},{"issue":"12","key":"2667_CR137","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41419-021-04401-4","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, et al. ALKBH5-mediated m(6)A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN\/AKT signaling. Cell Death Dis. 2021;12(12):1121.","journal-title":"Cell Death Dis"},{"issue":"6","key":"2667_CR138","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41556-025-01667-0","volume":"27","author":"Z Chen","year":"2025","unstructured":"Chen Z, et al. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Nat Cell Biol. 2025;27(6):1035\u201347.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"2667_CR139","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1080\/15592294.2022.2061117","volume":"17","author":"W Wang","year":"2022","unstructured":"Wang W, et al. M(6)A RNA demethylase FTO promotes the growth, migration and invasion of pancreatic cancer cells through inhibiting TFPI-2. Epigenetics. 2022;17(12):1738\u201352.","journal-title":"Epigenetics"},{"key":"2667_CR140","doi-asserted-by":"crossref","unstructured":"Garg R, et al. Targeting FTO Suppresses Pancreatic Carcinogenesis via Regulating Stem Cell Maintenance and EMT Pathway. Cancers (Basel). 2022;14(23).","DOI":"10.3390\/cancers14235919"},{"issue":"20","key":"2667_CR141","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1038\/s41388-022-02306-w","volume":"41","author":"Z Tan","year":"2022","unstructured":"Tan Z, et al. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner. Oncogene. 2022;41(20):2860\u201372.","journal-title":"Oncogene"},{"issue":"1","key":"2667_CR142","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41419-025-08049-2","volume":"16","author":"Z Tan","year":"2025","unstructured":"Tan Z, et al. M(6)A demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis. Cell Death Dis. 2025;16(1):784.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2667_CR143","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41419-023-06244-7","volume":"14","author":"J Lu","year":"2023","unstructured":"Lu J, et al. FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p\/WNT5A\/WNT pathway in PDAC. Cell Death Dis. 2023;14(11):713.","journal-title":"Cell Death Dis"},{"issue":"47","key":"2667_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406714","volume":"11","author":"YQ Zhu","year":"2024","unstructured":"Zhu YQ, et al. Epigenetic activation of the CMTM6-IGF2BP1-EP300 positive feedback loop drives gemcitabine resistance in pancreatic ductal adenocarcinoma. Adv Sci (Weinh). 2024;11(47):e2406714.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"2667_CR145","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.gendis.2022.02.014","volume":"10","author":"WX Peng","year":"2023","unstructured":"Peng WX, et al. N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2\/MYC axis. Genes Dis. 2023;10(2):554\u201367.","journal-title":"Genes Dis"},{"issue":"4","key":"2667_CR146","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.gastro.2025.03.019","volume":"169","author":"R Tang","year":"2025","unstructured":"Tang R, et al. Stromal stiffness-regulated IGF2BP2 in pancreatic cancer drives immune evasion via sphingomyelin metabolism. Gastroenterology. 2025;169(4):615-631.e32.","journal-title":"Gastroenterology"},{"issue":"1","key":"2667_CR147","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-022-01272-w","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022;15(1):52.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2667_CR148","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12935-025-03736-8","volume":"25","author":"X Pu","year":"2025","unstructured":"Pu X, et al. The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis. Cancer Cell Int. 2025;25(1):122.","journal-title":"Cancer Cell Int"},{"key":"2667_CR149","doi-asserted-by":"publisher","unstructured":"Liu Q, et al. LINC01963 promotes pancreatic ductal adenocarcinoma proliferation via METTL3\/IGF2BP2 axis-mediated m\u2076A modification of c-Myc. J Exp Clin Cancer Res. 2026. https:\/\/doi.org\/10.1186\/s13046-026-03650-5.","DOI":"10.1186\/s13046-026-03650-5"},{"issue":"18","key":"2667_CR150","doi-asserted-by":"publisher","first-page":"9922","DOI":"10.7150\/thno.117202","volume":"15","author":"S Lv","year":"2025","unstructured":"Lv S, et al. Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC. Theranostics. 2025;15(18):9922\u201343.","journal-title":"Theranostics"},{"key":"2667_CR151","doi-asserted-by":"crossref","unstructured":"Fu W, et al. UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma. Int J Oncol. 2023;62(4).","DOI":"10.3892\/ijo.2023.5500"},{"issue":"1","key":"2667_CR152","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s11658-024-00611-8","volume":"29","author":"W Jin","year":"2024","unstructured":"Jin W, et al. WTAP\/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc. Cell Mol Biol Lett. 2024;29(1):97.","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"2667_CR153","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41388-025-03654-z","volume":"45","author":"YL Liang","year":"2026","unstructured":"Liang YL, et al. USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3. Oncogene. 2026;45(3):383\u201397.","journal-title":"Oncogene"},{"issue":"1","key":"2667_CR154","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/s41419-025-08155-1","volume":"16","author":"L Liu","year":"2025","unstructured":"Liu L, et al. IGF2BP3 regulates EMP1 stability in an m(6)A-dependent manner and activates the TGF-\u03b2 pathway to promote pancreatic cancer invasion. Cell Death Dis. 2025;16(1):858.","journal-title":"Cell Death Dis"},{"issue":"Pt B","key":"2667_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113079","volume":"142","author":"Z Tan","year":"2024","unstructured":"Tan Z, et al. m(6)A reader YTHDF2 orchestrates CD8(+) T cell infiltration to promote pancreatic cancer progression and predicts clinical outcome. Int Immunopharmacol. 2024;142(Pt B):113079.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2667_CR156","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1038\/s41467-024-49105-3","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, et al. ZDHHC20-mediated S-palmitoylation of YTHDF3 stabilizes MYC mRNA to promote pancreatic cancer progression. Nat Commun. 2024;15(1):4642.","journal-title":"Nat Commun"},{"issue":"1","key":"2667_CR157","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-022-02285-6","volume":"41","author":"Y Hu","year":"2022","unstructured":"Hu Y, et al. A reciprocal feedback between N6-methyladenosine reader YTHDF3 and lncRNA DICER1-AS1 promotes glycolysis of pancreatic cancer through inhibiting maturation of miR-5586-5p. J Exp Clin Cancer Res. 2022;41(1):69.","journal-title":"J Exp Clin Cancer Res"},{"issue":"21","key":"2667_CR158","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/0008-5472.CAN-24-0927","volume":"84","author":"Z Xu","year":"2024","unstructured":"Xu Z, et al. KHSRP stabilizes m6A-modified transcripts to activate FAK signaling and promote pancreatic ductal adenocarcinoma progression. Cancer Res. 2024;84(21):3602\u201316.","journal-title":"Cancer Res"},{"key":"2667_CR159","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canlet.2021.07.016","volume":"518","author":"XT Huang","year":"2021","unstructured":"Huang XT, et al. HNRNPC impedes m(6)A-dependent anti-metastatic alternative splicing events in pancreatic ductal adenocarcinoma. Cancer Lett. 2021;518:196\u2013206.","journal-title":"Cancer Lett"},{"issue":"2","key":"2667_CR160","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/mdr2.70022","volume":"1","author":"J Li","year":"2025","unstructured":"Li J, et al. The dual role of exosomes in the tumor microenvironment: from pro-tumorigenic signaling to immune modulation. Med Research. 2025;1(2):257\u201384.","journal-title":"Med Research"},{"issue":"4","key":"2667_CR161","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.7150\/thno.122294","volume":"16","author":"T Huang","year":"2026","unstructured":"Huang T, et al. Lactylation-driven NSUN2-mediated RNA m5C modification promotes perineural invasion in pancreatic cancer. Theranostics. 2026;16(4):1782\u2013803.","journal-title":"Theranostics"},{"issue":"22","key":"2667_CR162","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1038\/s41388-022-02325-7","volume":"41","author":"SY Chen","year":"2022","unstructured":"Chen SY, et al. RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer. Oncogene. 2022;41(22):3162\u201376.","journal-title":"Oncogene"},{"issue":"1","key":"2667_CR163","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41420-023-01521-y","volume":"9","author":"G Zhang","year":"2023","unstructured":"Zhang G, et al. NSUN2 stimulates tumor progression via enhancing TIAM2 mRNA stability in pancreatic cancer. Cell Death Discov. 2023;9(1):219.","journal-title":"Cell Death Discov"},{"key":"2667_CR164","doi-asserted-by":"publisher","unstructured":"Zeng L, et al. NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis. Gut, 2026. https:\/\/doi.org\/10.1136\/gutjnl-2025-336541.","DOI":"10.1136\/gutjnl-2025-336541"},{"key":"2667_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103195","volume":"63","author":"R Yang","year":"2021","unstructured":"Yang R, et al. The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation. EBioMedicine. 2021;63:103195.","journal-title":"EBioMedicine"},{"key":"2667_CR166","doi-asserted-by":"crossref","unstructured":"Xie J, et al. The m(7)G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK\/ERK Signaling. Cancers (Basel). 2023;15(22).","DOI":"10.3390\/cancers15225454"},{"issue":"1","key":"2667_CR167","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41420-024-01862-2","volume":"10","author":"Q Meng","year":"2024","unstructured":"Meng Q, et al. ALYREF-JunD-SLC7A5 axis promotes pancreatic ductal adenocarcinoma progression through epitranscriptome-metabolism reprogramming and immune evasion. Cell Death Discov. 2024;10(1):97.","journal-title":"Cell Death Discov"},{"key":"2667_CR168","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jare.2025.01.040","volume":"77","author":"L Yu","year":"2025","unstructured":"Yu L, et al. CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1\/RIPK3\/MLKL pathway. J Adv Res. 2025;77:653\u201368.","journal-title":"J Adv Res"},{"issue":"7","key":"2667_CR169","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/cac2.12158","volume":"41","author":"JZ Wang","year":"2021","unstructured":"Wang JZ, et al. The role of the HIF-1\u03b1\/ALYREF\/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun (Lond). 2021;41(7):560\u201375.","journal-title":"Cancer Commun (Lond)"},{"issue":"14","key":"2667_CR170","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2321611121","volume":"121","author":"R Wu","year":"2024","unstructured":"Wu R, et al. NSUN5\/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. Proc Natl Acad Sci U S A. 2024;121(14):e2321611121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2667_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217064","volume":"597","author":"H Meng","year":"2024","unstructured":"Meng H, et al. YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification. Cancer Lett. 2024;597:217064.","journal-title":"Cancer Lett"},{"issue":"3","key":"2667_CR172","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cac2.12273","volume":"42","author":"J Chen","year":"2022","unstructured":"Chen J, et al. Aberrant translation regulated by METTL1\/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression. Cancer Commun (Lond). 2022;42(3):223\u201344.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"2667_CR173","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-024-03076-x","volume":"43","author":"D Du","year":"2024","unstructured":"Du D, et al. METTL1-mediated tRNA m(7)G methylation and translational dysfunction restricts breast cancer tumorigenesis by fueling cell cycle blockade. J Exp Clin Cancer Res. 2024;43(1):154.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2667_CR174","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13046-024-03132-6","volume":"43","author":"R Xu","year":"2024","unstructured":"Xu R, et al. tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB. J Exp Clin Cancer Res. 2024;43(1):230.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"2667_CR175","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1093\/nar\/gkad1193","volume":"52","author":"X Gu","year":"2024","unstructured":"Gu X, et al. Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A. Nucleic Acids Res. 2024;52(5):2273\u201389.","journal-title":"Nucleic Acids Res"},{"issue":"28","key":"2667_CR176","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119038119","volume":"119","author":"Y Wu","year":"2022","unstructured":"Wu Y, et al. RNA m(1)A methylation regulates glycolysis of cancer cells through modulating ATP5D. Proc Natl Acad Sci U S A. 2022;119(28):e2119038119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"2667_CR177","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202320029","volume":"63","author":"G Xie","year":"2024","unstructured":"Xie G, et al. Small Molecule-Inducible and Photoactivatable Cellular RNA N1-Methyladenosine Editing. Angew Chem Int Ed Engl. 2024;63(26):e202320029.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"2667_CR178","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41368-024-00304-0","volume":"16","author":"S Li","year":"2024","unstructured":"Li S, et al. m(1)A inhibition fuels oncolytic virus-elicited antitumor immunity via downregulating MYC\/PD-L1 signaling. Int J Oral Sci. 2024;16(1):36.","journal-title":"Int J Oral Sci"},{"issue":"6","key":"2667_CR179","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molmed.2024.03.008","volume":"30","author":"MC De Santis","year":"2024","unstructured":"De Santis MC, et al. Exploiting pancreatic cancer metabolism: challenges and opportunities. Trends Mol Med. 2024;30(6):592\u2013604.","journal-title":"Trends Mol Med"},{"key":"2667_CR180","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw5473","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"issue":"4","key":"2667_CR181","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10555-021-10004-4","volume":"40","author":"HB Andersen","year":"2021","unstructured":"Andersen HB, et al. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets. Cancer Metastasis Rev. 2021;40(4):1093\u2013114.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"2667_CR182","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927;8(6):519\u201330.","journal-title":"J Gen Physiol"},{"issue":"1","key":"2667_CR183","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen J, et al. Lactate and lactylation in cancer. Signal Transduct Target Ther. 2025;10(1):38.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2667_CR184","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41419-024-06435-w","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, et al. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. 2024;15(1):42.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2667_CR185","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, et al. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34(11):1675\u201399.","journal-title":"Cell Metab"},{"issue":"4","key":"2667_CR186","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tem.2022.01.005","volume":"33","author":"L Ippolito","year":"2022","unstructured":"Ippolito L, Sonveaux P, Chiarugi P. Unconventional roles of lactate along the tumor and immune landscape. Trends Endocrinol Metab. 2022;33(4):231\u20135.","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"2667_CR187","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","volume":"26","author":"J He","year":"2025","unstructured":"He J, et al. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer. Nat Immunol. 2025;26(3):391\u2013403.","journal-title":"Nat Immunol"},{"key":"2667_CR188","doi-asserted-by":"publisher","first-page":"1185985","DOI":"10.3389\/fimmu.2023.1185985","volume":"14","author":"X Liang","year":"2023","unstructured":"Liang X, et al. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma. Front Immunol. 2023;14:1185985.","journal-title":"Front Immunol"},{"issue":"8","key":"2667_CR189","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","volume":"15","author":"H Wu","year":"2024","unstructured":"Wu H, et al. Emerging mechanisms and promising approaches in pancreatic cancer metabolism. Cell Death Dis. 2024;15(8):553.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2667_CR190","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.cmet.2018.03.008","volume":"27","author":"GA Brooks","year":"2018","unstructured":"Brooks GA. The science and translation of lactate shuttle theory. Cell Metab. 2018;27(4):757\u201385.","journal-title":"Cell Metab"},{"issue":"6","key":"2667_CR191","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2006.04.023","volume":"9","author":"VR Fantin","year":"2006","unstructured":"Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9(6):425\u201334.","journal-title":"Cancer Cell"},{"issue":"46","key":"2667_CR192","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401399","volume":"11","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Lactylation-driven IGF2BP3-mediated serine metabolism reprogramming and RNA m6A-modification promotes lenvatinib resistance in HCC. Adv Sci Weinh. 2024;11(46):e2401399.","journal-title":"Adv Sci Weinh"},{"issue":"1","key":"2667_CR193","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1038\/s41467-023-42025-8","volume":"14","author":"L Sun","year":"2023","unstructured":"Sun L, et al. Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer. Nat Commun. 2023;14(1):6523.","journal-title":"Nat Commun"},{"issue":"9","key":"2667_CR194","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.molcel.2022.02.033","volume":"82","author":"J Xiong","year":"2022","unstructured":"Xiong J, et al. Lactylation-driven METTL3-mediated RNA m(6)A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. 2022;82(9):1660-1677.e10.","journal-title":"Mol Cell"},{"issue":"1","key":"2667_CR195","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10565-024-09951-9","volume":"40","author":"F Tang","year":"2024","unstructured":"Tang F, et al. The roles of lactate and the interplay with m(6)A modification in diseases. Cell Biol Toxicol. 2024;40(1):107.","journal-title":"Cell Biol Toxicol"},{"issue":"33","key":"2667_CR196","doi-asserted-by":"publisher","first-page":"20159","DOI":"10.1073\/pnas.1918986117","volume":"117","author":"N Li","year":"2020","unstructured":"Li N, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020;117(33):20159\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2667_CR197","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/s41418-021-00804-0","volume":"28","author":"Y Hou","year":"2021","unstructured":"Hou Y, et al. YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect. Cell Death Differ. 2021;28(11):3105\u201324.","journal-title":"Cell Death Differ"},{"key":"2667_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106555","volume":"187","author":"F Li","year":"2023","unstructured":"Li F, et al. Glutamate from nerve cells promotes perineural invasion in pancreatic cancer by regulating tumor glycolysis through HK2 mRNA-m6A modification. Pharmacol Res. 2023;187:106555.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2667_CR199","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-024-03898-w","volume":"74","author":"S Zhang","year":"2024","unstructured":"Zhang S, et al. Targeting OAS3 for reversing M2d infiltration and restoring anti-tumor immunity in pancreatic cancer. Cancer Immunol Immunother. 2024;74(1):37.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2667_CR200","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.cmet.2025.07.008","volume":"37","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. Cell Metab. 2025;37(9):1907-1925.e14.","journal-title":"Cell Metab"},{"issue":"1","key":"2667_CR201","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27\u201347.","journal-title":"Cell Metab"},{"issue":"11","key":"2667_CR202","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/procel\/pwaf029","volume":"16","author":"M Wang","year":"2025","unstructured":"Wang M, et al. Glutamine signaling specifically activates c-Myc and Mcl-1 to facilitate cancer cell proliferation and survival. Protein Cell. 2025;16(11):968\u201384.","journal-title":"Protein Cell"},{"key":"2667_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.962204","volume":"12","author":"Z Guo","year":"2022","unstructured":"Guo Z, et al. METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Front Oncol. 2022;12:962204.","journal-title":"Front Oncol"},{"issue":"25","key":"2667_CR204","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj8650","volume":"10","author":"H Sun","year":"2024","unstructured":"Sun H, et al. BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Sci Adv. 2024;10(25):eadj8650.","journal-title":"Sci Adv"},{"issue":"1","key":"2667_CR205","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13045-023-01498-2","volume":"16","author":"HR Jin","year":"2023","unstructured":"Jin HR, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"2667_CR206","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1158\/0008-5472.CAN-20-1255","volume":"80","author":"CN Rozeveld","year":"2020","unstructured":"Rozeveld CN, et al. KRAS Controls Pancreatic Cancer Cell Lipid Metabolism and Invasive Potential through the Lipase HSL. Cancer Res. 2020;80(22):4932\u201345.","journal-title":"Cancer Res"},{"issue":"8","key":"2667_CR207","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/cac2.70038","volume":"45","author":"M Lao","year":"2025","unstructured":"Lao M, et al. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer Commun (Lond). 2025;45(8):1010\u201337.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"2667_CR208","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s43018-023-00703-y","volume":"5","author":"S Bhattacharyya","year":"2024","unstructured":"Bhattacharyya S, et al. Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Nat Cancer. 2024;5(2):283\u201398.","journal-title":"Nat Cancer"},{"issue":"2","key":"2667_CR209","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/gutjnl-2021-325117","volume":"72","author":"MC De Santis","year":"2023","unstructured":"De Santis MC, et al. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. Gut. 2023;72(2):360\u201371.","journal-title":"Gut"},{"issue":"1","key":"2667_CR210","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/s41467-025-56894-8","volume":"16","author":"A Garc\u00eda Garc\u00eda","year":"2025","unstructured":"Garc\u00eda Garc\u00eda A, et al. Targeting ELOVL6 to disrupt c-MYC driven lipid metabolism in pancreatic cancer enhances chemosensitivity. Nat Commun. 2025;16(1):1694.","journal-title":"Nat Commun"},{"issue":"31","key":"2667_CR211","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41388-024-03092-3","volume":"43","author":"MJ Ma","year":"2024","unstructured":"Ma MJ, et al. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Oncogene. 2024;43(31):2405\u201320.","journal-title":"Oncogene"},{"issue":"1","key":"2667_CR212","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41420-024-02020-4","volume":"10","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1\/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma. Cell Death Discov. 2024;10(1):252.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2667_CR213","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/s12967-023-04578-6","volume":"21","author":"J Chen","year":"2023","unstructured":"Chen J, et al. ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner. J Transl Med. 2023;21(1):741.","journal-title":"J Transl Med"},{"issue":"4","key":"2667_CR214","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.7150\/ijbs.103428","volume":"21","author":"J Chen","year":"2025","unstructured":"Chen J, et al. FTO-induced APOE promotes the malignant progression of pancreatic neuroendocrine neoplasms through FASN-mediated lipid metabolism. Int J Biol Sci. 2025;21(4):1478\u201396.","journal-title":"Int J Biol Sci"},{"issue":"7986","key":"2667_CR215","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41586-023-06685-2","volume":"623","author":"N Caronni","year":"2023","unstructured":"Caronni N, et al. IL-1\u03b2(+) macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623(7986):415\u201322.","journal-title":"Nature"},{"issue":"12","key":"2667_CR216","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1136\/gutjnl-2022-329349","volume":"72","author":"X Liu","year":"2023","unstructured":"Liu X, et al. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-\u03baB\/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Gut. 2023;72(12):2329\u201343.","journal-title":"Gut"},{"issue":"Pt 2","key":"2667_CR217","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2022.08.009","volume":"86","author":"X Li","year":"2022","unstructured":"Li X, et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol. 2022;86(Pt 2):14\u201327.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2667_CR218","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.ccell.2025.06.020","volume":"43","author":"MM Chen","year":"2025","unstructured":"Chen MM, et al. Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer. Cancer Cell. 2025;43(9):1656-1676.e10.","journal-title":"Cancer Cell"},{"key":"2667_CR219","doi-asserted-by":"crossref","unstructured":"Mota Reyes C, et al. Regulatory T Cells in Pancreatic Cancer: Of Mice and Men. Cancers (Basel). 2022;14(19).","DOI":"10.3390\/cancers14194582"},{"key":"2667_CR220","doi-asserted-by":"publisher","first-page":"1271603","DOI":"10.3389\/fimmu.2023.1271603","volume":"14","author":"Z Ou","year":"2023","unstructured":"Ou Z, et al. Hypoxia mediates immune escape of pancreatic cancer cells by affecting miR-1275\/AXIN2 in natural killer cells. Front Immunol. 2023;14:1271603.","journal-title":"Front Immunol"},{"issue":"1","key":"2667_CR221","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s13046-024-03192-8","volume":"43","author":"B Zhang","year":"2024","unstructured":"Zhang B, et al. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2024;43(1):271.","journal-title":"J Exp Clin Cancer Res"},{"key":"2667_CR222","doi-asserted-by":"publisher","first-page":"1582305","DOI":"10.3389\/fimmu.2025.1582305","volume":"16","author":"D Pan","year":"2025","unstructured":"Pan D, et al. Immunosuppressive tumor microenvironment in pancreatic cancer: mechanisms and therapeutic targets. Front Immunol. 2025;16:1582305.","journal-title":"Front Immunol"},{"key":"2667_CR223","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.matbio.2022.11.002","volume":"114","author":"B Yan","year":"2022","unstructured":"Yan B, et al. Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Matrix Biol. 2022;114:84\u2013107.","journal-title":"Matrix Biol"},{"issue":"8","key":"2667_CR224","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41416-022-01927-y","volume":"127","author":"T Zhao","year":"2022","unstructured":"Zhao T, et al. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1\u03b2\/NF-\u03baB\/ESE3 signalling axis. Br J Cancer. 2022;127(8):1461\u201372.","journal-title":"Br J Cancer"},{"key":"2667_CR225","doi-asserted-by":"crossref","unstructured":"Liu A, et al. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration. JCI Insight. 2024;9(1).","DOI":"10.1172\/jci.insight.169150"},{"key":"2667_CR226","doi-asserted-by":"publisher","unstructured":"Mahat DB, et al. Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer. bioRxiv, 2024. https:\/\/doi.org\/10.1016\/j.immuni.2025.06.005.","DOI":"10.1016\/j.immuni.2025.06.005"},{"issue":"6","key":"2667_CR227","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1053\/j.gastro.2025.01.244","volume":"168","author":"D Yang","year":"2025","unstructured":"Yang D, et al. TREM2 depletion in pancreatic cancer elicits pathogenic inflammation and accelerates tumor progression via enriching IL-1\u03b2(+) macrophages. Gastroenterology. 2025;168(6):1153\u201369.","journal-title":"Gastroenterology"},{"key":"2667_CR228","doi-asserted-by":"publisher","first-page":"1157397","DOI":"10.3389\/fimmu.2023.1157397","volume":"14","author":"T Daunke","year":"2023","unstructured":"Daunke T, et al. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Front Immunol. 2023;14:1157397.","journal-title":"Front Immunol"},{"key":"2667_CR229","doi-asserted-by":"crossref","unstructured":"Rigopoulos CP, et al. Epitranscriptomics Regulation of CD70, CD80, and TIGIT in Cancer Immunity. Int J Mol Sci. 2025;26(12).","DOI":"10.3390\/ijms26125772"},{"issue":"12","key":"2667_CR230","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41419-023-06241-w","volume":"14","author":"B Chen","year":"2023","unstructured":"Chen B, et al. m6A and m5C modification of GPX4 facilitates anticancer immunity via STING activation. Cell Death Dis. 2023;14(12):809.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2667_CR231","doi-asserted-by":"publisher","first-page":"C762","DOI":"10.1152\/ajpcell.00212.2019","volume":"317","author":"Y Liu","year":"2019","unstructured":"Liu Y, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA. Am J Physiol Cell Physiol. 2019;317(4):C762-c775.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2667_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109553","volume":"69","author":"X Gu","year":"2020","unstructured":"Gu X, et al. N6-methyladenosine demethylase FTO promotes M1 and M2 macrophage activation. Cell Signal. 2020;69:109553.","journal-title":"Cell Signal"},{"issue":"1","key":"2667_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21514-8","volume":"12","author":"H Yin","year":"2021","unstructured":"Yin H, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12(1):1394.","journal-title":"Nat Commun"},{"issue":"4","key":"2667_CR234","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41418-024-01423-1","volume":"32","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Cell Death Differ. 2025;32(4):745\u201362.","journal-title":"Cell Death Differ"},{"issue":"7667","key":"2667_CR235","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature23450","volume":"548","author":"HB Li","year":"2017","unstructured":"Li HB, et al. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7\/STAT5\/SOCS pathways. Nature. 2017;548(7667):338\u201342.","journal-title":"Nature"},{"issue":"2","key":"2667_CR236","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cell.2024.11.007","volume":"188","author":"Z Chen","year":"2025","unstructured":"Chen Z, et al. YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell. 2025;188(2):331-351.e30.","journal-title":"Cell"},{"issue":"6","key":"2667_CR237","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33(6):1221-1233.e11.","journal-title":"Cell Metab"},{"issue":"1","key":"2667_CR238","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41419-025-08378-2","volume":"17","author":"J Chen","year":"2025","unstructured":"Chen J, et al. FUT2 enhances anti-tumor immunity in pancreatic cancer radiotherapy by driving FBXO2-mediated degradation of NR2F2. Cell Death Dis. 2025;17(1):126.","journal-title":"Cell Death Dis"},{"key":"2667_CR239","doi-asserted-by":"crossref","unstructured":"Miao S, et al. tRNA m1A modification regulates cholesterol biosynthesis to promote antitumor immunity of CD8+ T cells. J Exp Med. 2025;222(3).","DOI":"10.1084\/jem.20240559"},{"issue":"4","key":"2667_CR240","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00262-025-03986-5","volume":"74","author":"Y Yang","year":"2025","unstructured":"Yang Y, et al. NSUN2\/ALYREF axis-driven m(5)C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer. Cancer Immunol Immunother. 2025;74(4):132.","journal-title":"Cancer Immunol Immunother"},{"issue":"7743","key":"2667_CR241","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-0916-x","volume":"566","author":"D Han","year":"2019","unstructured":"Han D, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270\u20134.","journal-title":"Nature"},{"issue":"1","key":"2667_CR242","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41467-019-09903-6","volume":"10","author":"H Wang","year":"2019","unstructured":"Wang H, et al. Mettl3-mediated mRNA m(6)A methylation promotes dendritic cell activation. Nat Commun. 2019;10(1):1898.","journal-title":"Nat Commun"},{"issue":"1","key":"2667_CR243","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10.","journal-title":"Mol Cancer"},{"key":"2667_CR244","doi-asserted-by":"publisher","first-page":"1004212","DOI":"10.3389\/fonc.2022.1004212","volume":"12","author":"Z Song","year":"2022","unstructured":"Song Z, et al. LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer. Front Oncol. 2022;12:1004212.","journal-title":"Front Oncol"},{"issue":"2","key":"2667_CR245","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41419-023-05570-0","volume":"14","author":"H Guan","year":"2023","unstructured":"Guan H, et al. m(6)A-modified circRNA MYO1C participates in the tumor immune surveillance of pancreatic ductal adenocarcinoma through m(6)A\/PD-L1 manner. Cell Death Dis. 2023;14(2):120.","journal-title":"Cell Death Dis"},{"key":"2667_CR246","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.759020","volume":"10","author":"L Lu","year":"2022","unstructured":"Lu L, et al. METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma. Front Cell Dev Biol. 2022;10:759020.","journal-title":"Front Cell Dev Biol"},{"key":"2667_CR247","doi-asserted-by":"publisher","first-page":"1621927","DOI":"10.3389\/fimmu.2025.1621927","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, et al. Multiomics profiling Identifies MCMBP as a prognostic biomarker and a potential immune-related target in pancreatic ductal adenocarcinoma via the JAK-STAT3 pathway. Front Immunol. 2025;16:1621927.","journal-title":"Front Immunol"},{"issue":"1","key":"2667_CR248","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1186\/s12885-023-11524-8","volume":"23","author":"L Li","year":"2023","unstructured":"Li L, et al. DCLRE1B promotes tumor progression and predicts immunotherapy response through METTL3-mediated m6A modification in pancreatic cancer. BMC Cancer. 2023;23(1):1073.","journal-title":"BMC Cancer"},{"issue":"3","key":"2667_CR249","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/med4.27","volume":"1","author":"M Huang","year":"2023","unstructured":"Huang M, et al. Crosstalk between cancer cells and the nervous system. Medicine Advances. 2023;1(3):173\u201389.","journal-title":"Medicine Advances"},{"issue":"25","key":"2667_CR250","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41388-023-02704-8","volume":"42","author":"X Liu","year":"2023","unstructured":"Liu X, et al. M6A methylation regulates hypoxia-induced pancreatic cancer glycolytic metabolism through ALKBH5-HDAC4-HIF1\u03b1 positive feedback loop. Oncogene. 2023;42(25):2047\u201360.","journal-title":"Oncogene"},{"issue":"1","key":"2667_CR251","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1186\/s12967-023-04757-5","volume":"21","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, et al. GATA6-AS1 suppresses epithelial-mesenchymal transition of pancreatic cancer under hypoxia through regulating SNAI1 mRNA stability. J Transl Med. 2023;21(1):882.","journal-title":"J Transl Med"},{"issue":"1","key":"2667_CR252","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-020-00453-8","volume":"6","author":"Q Li","year":"2021","unstructured":"Li Q, et al. HIF-1\u03b1-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation. Signal Transduct Target Ther. 2021;6(1):76.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2667_CR253","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1053\/j.gastro.2022.02.024","volume":"162","author":"CJ Garcia Garcia","year":"2022","unstructured":"Garcia Garcia CJ, et al. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Gastroenterology. 2022;162(7):2018\u201331.","journal-title":"Gastroenterology"},{"issue":"3","key":"2667_CR254","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccell.2023.01.009","volume":"41","author":"EN Arner","year":"2023","unstructured":"Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421\u201333.","journal-title":"Cancer Cell"},{"key":"2667_CR255","doi-asserted-by":"publisher","unstructured":"Zhu D, Shen R, Li M. METTL3 promotes pancreatic cancer immune escape by m6A modification of lncRNA AFAP1-AS1 to enhance EGR2 stability. Eur J Med Res. 2026. https:\/\/doi.org\/10.1186\/s40001-026-03963-3.","DOI":"10.1186\/s40001-026-03963-3"},{"issue":"1","key":"2667_CR256","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13073-021-01002-w","volume":"13","author":"Y Ye","year":"2021","unstructured":"Ye Y, et al. Genome-wide identification and characterization of circular RNA m(6)A modification in pancreatic cancer. Genome Med. 2021;13(1):183.","journal-title":"Genome Med"},{"issue":"1","key":"2667_CR257","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molcel.2019.07.016","volume":"76","author":"YG Chen","year":"2019","unstructured":"Chen YG, et al. N6-Methyladenosine Modification Controls Circular RNA Immunity. Mol Cell. 2019;76(1):96-109.e9.","journal-title":"Mol Cell"},{"key":"2667_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217699","volume":"622","author":"K Br\u00e4utigam","year":"2025","unstructured":"Br\u00e4utigam K, et al. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - Exploring the \u201cSpace.\u201d Cancer Lett. 2025;622:217699.","journal-title":"Cancer Lett"},{"issue":"6","key":"2667_CR259","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s43018-023-00562-7","volume":"4","author":"H Damhofer","year":"2023","unstructured":"Damhofer H, Helin K. EZH2i unlocks PDAC immune surveillance. Nat Cancer. 2023;4(6):781\u20133.","journal-title":"Nat Cancer"},{"issue":"6","key":"2667_CR260","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110813","volume":"39","author":"ZW Wang","year":"2022","unstructured":"Wang ZW, et al. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Cell Rep. 2022;39(6):110813.","journal-title":"Cell Rep"},{"issue":"1","key":"2667_CR261","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1038\/s41467-023-41861-y","volume":"14","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, et al. CSTF2 mediated mRNA N(6)-methyladenosine modification drives pancreatic ductal adenocarcinoma m(6)A subtypes. Nat Commun. 2023;14(1):6334.","journal-title":"Nat Commun"},{"issue":"7","key":"2667_CR262","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1111\/cas.16152","volume":"115","author":"T Hara","year":"2024","unstructured":"Hara T, et al. High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker. Cancer Sci. 2024;115(7):2360\u201370.","journal-title":"Cancer Sci"},{"issue":"1","key":"2667_CR263","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1038\/s41598-022-07112-8","volume":"12","author":"Q Wu","year":"2022","unstructured":"Wu Q, et al. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma. Sci Rep. 2022;12(1):3079.","journal-title":"Sci Rep"},{"key":"2667_CR264","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.omto.2020.04.011","volume":"17","author":"Z Meng","year":"2020","unstructured":"Meng Z, et al. The m(6)A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients. Mol Ther Oncolytics. 2020;17:460\u201370.","journal-title":"Mol Ther Oncolytics"},{"key":"2667_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103271","volume":"65","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, et al. An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine. 2021;65:103271.","journal-title":"EBioMedicine"},{"issue":"1","key":"2667_CR266","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12885-024-11885-8","volume":"24","author":"XQ Li","year":"2024","unstructured":"Li XQ, et al. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma. BMC Cancer. 2024;24(1):116.","journal-title":"BMC Cancer"},{"issue":"31","key":"2667_CR267","doi-asserted-by":"publisher","first-page":"16822","DOI":"10.1021\/acs.analchem.5c01864","volume":"97","author":"S Sun","year":"2025","unstructured":"Sun S, et al. Exploring site-specific N(6)-methyladenosine modifications as new cancer biomarkers via SERS-based single-cell assay and histopathological imaging. Anal Chem. 2025;97(31):16822\u201331.","journal-title":"Anal Chem"},{"issue":"1","key":"2667_CR268","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42832-z","volume":"14","author":"K Hartstock","year":"2023","unstructured":"Hartstock K, et al. MePMe-seq: antibody-free simultaneous m(6)A and m(5)C mapping in mRNA by metabolic propargyl labeling and sequencing. Nat Commun. 2023;14(1):7154.","journal-title":"Nat Commun"},{"issue":"1","key":"2667_CR269","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1186\/s12967-024-05528-6","volume":"22","author":"MM Konat\u00e9","year":"2024","unstructured":"Konat\u00e9 MM, et al. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts. J Transl Med. 2024;22(1):733.","journal-title":"J Transl Med"},{"issue":"1","key":"2667_CR270","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13046-023-02792-0","volume":"42","author":"K Lin","year":"2023","unstructured":"Lin K, et al. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN\/PI3K\/AKT pathway. J Exp Clin Cancer Res. 2023;42(1):217.","journal-title":"J Exp Clin Cancer Res"},{"key":"2667_CR271","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696371","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, et al. M(6)A methyltransferase METTL14-mediated upregulation of cytidine deaminase promoting gemcitabine resistance in pancreatic cancer. Front Oncol. 2021;11:696371.","journal-title":"Front Oncol"},{"issue":"1","key":"2667_CR272","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s10020-025-01285-4","volume":"31","author":"Q Wang","year":"2025","unstructured":"Wang Q, et al. O-GlcNAcylation with ubiquitination stabilizes METTL3 to promoting HMGB1 degradation to inhibit ferroptosis and enhance gemcitabine resistance in pancreatic cancer. Mol Med. 2025;31(1):228.","journal-title":"Mol Med"},{"issue":"8","key":"2667_CR273","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202510483","volume":"13","author":"XT Huang","year":"2026","unstructured":"Huang XT, et al. Positive Feedback Loop of Histone Lactylation-Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance. Adv Sci (Weinh). 2026;13(8):e10483.","journal-title":"Adv Sci (Weinh)"},{"issue":"18","key":"2667_CR274","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/0008-5472.CAN-22-3346","volume":"83","author":"J Su","year":"2023","unstructured":"Su J, et al. N 6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer. Cancer Res. 2023;83(18):3059\u201376.","journal-title":"Cancer Res"},{"issue":"11","key":"2667_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116476","volume":"44","author":"F Ge","year":"2025","unstructured":"Ge F, et al. IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC. Cell Rep. 2025;44(11):116476.","journal-title":"Cell Rep"},{"issue":"1","key":"2667_CR276","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13062-022-00347-5","volume":"17","author":"C Lin","year":"2022","unstructured":"Lin C, et al. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Biol Direct. 2022;17(1):33.","journal-title":"Biol Direct"},{"issue":"1","key":"2667_CR277","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12935-023-03181-5","volume":"24","author":"L Ouyang","year":"2024","unstructured":"Ouyang L, et al. LncRNA FOXD1-AS1 regulates pancreatic cancer stem cell properties and 5-FU resistance by regulating the miR-570-3p\/SPP1 axis as a ceRNA. Cancer Cell Int. 2024;24(1):4.","journal-title":"Cancer Cell Int"},{"issue":"15","key":"2667_CR278","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.7150\/thno.112612","volume":"15","author":"G Li","year":"2025","unstructured":"Li G, et al. Tetrahydromagnolol induces autophagic cell death by targeting the m(6)A reader protein YTHDF2 and enhances the efficacy of anti-PD-1 immunotherapy in pancreatic cancer cells. Theranostics. 2025;15(15):7726\u201346.","journal-title":"Theranostics"},{"issue":"1","key":"2667_CR279","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22(1):91.","journal-title":"Mol Cancer"},{"issue":"22","key":"2667_CR280","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","volume":"28","author":"HL Kindler","year":"2010","unstructured":"Kindler HL, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617\u201322.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2667_CR281","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960\u20136.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2667_CR282","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"34","key":"2667_CR283","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022;40(34):3929\u201339.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2667_CR284","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res. 2019;25(13):3753\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2667_CR285","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"2667_CR286","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21(4):531\u201340.","journal-title":"Lancet Oncol"},{"key":"2667_CR287","doi-asserted-by":"crossref","unstructured":"Strickler JH, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388(1):33\u201343.","DOI":"10.1056\/NEJMoa2208470"},{"issue":"25","key":"2667_CR288","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, et al. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J Clin Oncol. 2023;41(25):4097\u2013106.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2667_CR289","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, et al. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025;392(6):566\u201376.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR290","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-024-01595-w","volume":"17","author":"KI Zhou","year":"2024","unstructured":"Zhou KI, Strickler JH, Chen H. Targeting claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting. J Hematol Oncol. 2024;17(1):73.","journal-title":"J Hematol Oncol"},{"key":"2667_CR291","doi-asserted-by":"crossref","unstructured":"Lyu SI, et al. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Transl Oncol. 2024;47:102044.","DOI":"10.1016\/j.tranon.2024.102044"},{"key":"2667_CR292","doi-asserted-by":"crossref","unstructured":"Luchini C, et al. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Virchows Arch. 2025;487(3):487\u2013499.","DOI":"10.1007\/s00428-025-04222-2"},{"issue":"27","key":"2667_CR293","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38(27):3185\u201394.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2667_CR294","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","volume":"25","author":"JL Van Laethem","year":"2024","unstructured":"Van Laethem JL, et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol. 2024;25(7):853\u201364.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2667_CR295","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","volume":"29","author":"Y Boucher","year":"2023","unstructured":"Boucher Y, et al. Addition of losartan to FOLFIRINOX and chemoradiation reduces immunosuppression-associated genes, Tregs, and FOXP3+ cancer cells in locally advanced pancreatic cancer. Clin Cancer Res. 2023;29(8):1605\u201319.","journal-title":"Clin Cancer Res"},{"issue":"7860","key":"2667_CR296","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597\u2013601.","journal-title":"Nature"},{"issue":"11","key":"2667_CR297","doi-asserted-by":"publisher","first-page":"8852","DOI":"10.3390\/cimb45110555","volume":"45","author":"S Hao","year":"2023","unstructured":"Hao S, et al. STM2457 inhibits the invasion and metastasis of pancreatic cancer by down-regulating BRAF-activated noncoding RNA N6-methyladenosine modification. Curr Issues Mol Biol. 2023;45(11):8852\u201363.","journal-title":"Curr Issues Mol Biol"},{"issue":"19","key":"2667_CR298","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1002\/cmdc.202100291","volume":"16","author":"EV Moroz-Omori","year":"2021","unstructured":"Moroz-Omori EV, et al. METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes. ChemMedChem. 2021;16(19):3035\u201343.","journal-title":"ChemMedChem"},{"key":"2667_CR299","doi-asserted-by":"crossref","unstructured":"Dolbois A, et al. 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors. J Med Chem. 2021;64(17):12738\u201312760.","DOI":"10.1021\/acs.jmedchem.1c00773"},{"issue":"3","key":"2667_CR300","first-page":"783","volume":"83","author":"JH Lee","year":"2022","unstructured":"Lee JH, et al. Discovery of substituted indole derivatives as allosteric inhibitors of m(6) A-RNA methyltransferase, METTL3-14 complex. Drug Dev Res. 2022;83(3):783\u201399.","journal-title":"Drug Dev Res"},{"key":"2667_CR301","doi-asserted-by":"crossref","unstructured":"Lee JH, et al. Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the m(6)A Methylation of RNA in Acute Myeloid Leukemia Cells. Pharmaceuticals (Basel). 2022;15(4).","DOI":"10.3390\/ph15040440"},{"issue":"4","key":"2667_CR302","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","volume":"35","author":"Y Huang","year":"2019","unstructured":"Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019;35(4):677-691.e10.","journal-title":"Cancer Cell"},{"issue":"1","key":"2667_CR303","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ccell.2020.04.017","volume":"38","author":"R Su","year":"2020","unstructured":"Su R, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020;38(1):79-96.e11.","journal-title":"Cancer Cell"},{"issue":"21","key":"2667_CR304","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1021\/acs.accounts.3c00451","volume":"56","author":"Y Huang","year":"2023","unstructured":"Huang Y, et al. Chemical inhibitors targeting the oncogenic m(6)A modifying proteins. Acc Chem Res. 2023;56(21):3010\u201322.","journal-title":"Acc Chem Res"},{"issue":"43","key":"2667_CR305","doi-asserted-by":"publisher","first-page":"17963","DOI":"10.1021\/ja3064149","volume":"134","author":"B Chen","year":"2012","unstructured":"Chen B, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J Am Chem Soc. 2012;134(43):17963\u201371.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"2667_CR306","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.apsb.2021.08.028","volume":"12","author":"G Xie","year":"2022","unstructured":"Xie G, et al. A novel inhibitor of N (6)-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharm Sin B. 2022;12(2):853\u201366.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"2667_CR307","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1021\/acschembio.0c00841","volume":"16","author":"S Huff","year":"2021","unstructured":"Huff S, et al. m(6)A-RNA demethylase FTO inhibitors impair self-renewal in glioblastoma stem cells. ACS Chem Biol. 2021;16(2):324\u201333.","journal-title":"ACS Chem Biol"},{"issue":"1","key":"2667_CR308","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/nar\/gku1276","volume":"43","author":"Y Huang","year":"2015","unstructured":"Huang Y, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res. 2015;43(1):373\u201384.","journal-title":"Nucleic Acids Res"},{"key":"2667_CR309","doi-asserted-by":"crossref","unstructured":"Peng S, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci Transl Med. 2019;11(488).","DOI":"10.1126\/scitranslmed.aau7116"},{"issue":"1\u20132","key":"2667_CR310","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cell.2017.11.031","volume":"172","author":"R Su","year":"2018","unstructured":"Su R, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO\/m(6)A\/MYC\/CEBPA Signaling. Cell. 2018;172(1\u20132):90-105.e23.","journal-title":"Cell"},{"issue":"16","key":"2667_CR311","doi-asserted-by":"publisher","first-page":"10920","DOI":"10.1021\/acs.jmedchem.1c02075","volume":"65","author":"S Huff","year":"2022","unstructured":"Huff S, et al. Rational design and optimization of m(6)A-RNA demethylase FTO inhibitors as anticancer agents. J Med Chem. 2022;65(16):10920\u201337.","journal-title":"J Med Chem"},{"issue":"14","key":"2667_CR312","doi-asserted-by":"publisher","first-page":"9731","DOI":"10.1021\/acs.jmedchem.3c00543","volume":"66","author":"P Xiao","year":"2023","unstructured":"Xiao P, et al. Rational design of RNA demethylase FTO inhibitors with enhanced antileukemia drug-like properties. J Med Chem. 2023;66(14):9731\u201352.","journal-title":"J Med Chem"},{"issue":"1","key":"2667_CR313","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1080\/14756366.2022.2098954","volume":"37","author":"B Qin","year":"2022","unstructured":"Qin B, et al. Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer. J Enzyme Inhib Med Chem. 2022;37(1):1995\u20132003.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"9","key":"2667_CR314","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1021\/acs.molpharmaceut.8b00522","volume":"15","author":"R Wang","year":"2018","unstructured":"Wang R, et al. Identification of natural compound radicicol as a potent FTO inhibitor. Mol Pharm. 2018;15(9):4092\u20138.","journal-title":"Mol Pharm"},{"issue":"15","key":"2667_CR315","doi-asserted-by":"publisher","first-page":"10638","DOI":"10.1021\/acs.jmedchem.2c00848","volume":"65","author":"Z Liu","year":"2022","unstructured":"Liu Z, et al. Structure-activity relationships and antileukemia effects of the tricyclic benzoic acid FTO inhibitors. J Med Chem. 2022;65(15):10638\u201354.","journal-title":"J Med Chem"},{"issue":"4","key":"2667_CR316","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115300","volume":"28","author":"A Malacrida","year":"2020","unstructured":"Malacrida A, et al. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorg Med Chem. 2020;28(4):115300.","journal-title":"Bioorg Med Chem"},{"issue":"23","key":"2667_CR317","doi-asserted-by":"publisher","first-page":"15944","DOI":"10.1021\/acs.jmedchem.3c01374","volume":"66","author":"YZ Wang","year":"2023","unstructured":"Wang YZ, et al. Discovery of Pyrazolo[1,5-a]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML. J Med Chem. 2023;66(23):15944\u201359.","journal-title":"J Med Chem"},{"issue":"20","key":"2667_CR318","doi-asserted-by":"publisher","first-page":"13310","DOI":"10.1021\/acsomega.1c01289","volume":"6","author":"S Selberg","year":"2021","unstructured":"Selberg S, et al. Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors. ACS Omega. 2021;6(20):13310\u201320.","journal-title":"ACS Omega"},{"issue":"7","key":"2667_CR319","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41(7):1294-1308.e8.","journal-title":"Cancer Cell"},{"issue":"6","key":"2667_CR320","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/0008-5472.CAN-21-4249","volume":"83","author":"YG Hong","year":"2023","unstructured":"Hong YG, et al. The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression. Cancer Res. 2023;83(6):845\u201360.","journal-title":"Cancer Res"},{"issue":"5","key":"2667_CR321","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.tranon.2017.07.008","volume":"10","author":"L Mahapatra","year":"2017","unstructured":"Mahapatra L, et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl Oncol. 2017;10(5):818\u201327.","journal-title":"Transl Oncol"},{"issue":"8","key":"2667_CR322","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acscentsci.2c00107","volume":"8","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment. ACS Cent Sci. 2022;8(8):1102\u201315.","journal-title":"ACS Cent Sci"},{"issue":"9","key":"2667_CR323","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/s41375-022-01651-9","volume":"36","author":"P Feng","year":"2022","unstructured":"Feng P, et al. Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia. Leukemia. 2022;36(9):2180\u20138.","journal-title":"Leukemia"},{"issue":"12","key":"2667_CR324","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.ccell.2022.10.004","volume":"40","author":"H Weng","year":"2022","unstructured":"Weng H, et al. The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40(12):1566-1582.e10.","journal-title":"Cancer Cell"},{"issue":"12","key":"2667_CR325","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1136\/gutjnl-2019-320179","volume":"69","author":"J Tian","year":"2020","unstructured":"Tian J, et al. N(6)-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut. 2020;69(12):2180\u201392.","journal-title":"Gut"},{"key":"2667_CR326","doi-asserted-by":"publisher","unstructured":"<moser-et-al-2024-phase-1-dose-escalation-and-cohort-expansion-study-evaluating-safety-pk-pd-and-clinical-activity-of.pdf>. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2586.","DOI":"10.1200\/JCO.2024.42.16_suppl.2586"},{"key":"2667_CR327","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117444","volume":"289","author":"D Zhang","year":"2025","unstructured":"Zhang D, et al. Development of 3-arylaminothiophenic-2-carboxylic acid derivatives as new FTO inhibitors showing potent antileukemia activities. Eur J Med Chem. 2025;289:117444.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"2667_CR328","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28243","volume":"10","author":"D Chen","year":"2024","unstructured":"Chen D, et al. IGF2BP2-related modification patterns in pancreatic cancer: a machine learning-driven approach towards personalized treatment. Heliyon. 2024;10(6):e28243.","journal-title":"Heliyon"},{"issue":"10","key":"2667_CR329","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/s41418-023-01225-x","volume":"30","author":"G Wu","year":"2023","unstructured":"Wu G, et al. LncRNA BCAN-AS1 stabilizes c-Myc via N(6)-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Cell Death Differ. 2023;30(10):2213\u201330.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2667_CR330","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neuron.2025.10.002","volume":"114","author":"X Yang","year":"2026","unstructured":"Yang X, et al. METTL14 integrates tumor-derived SAM to drive parabrachial epigenetic rewiring in pancreatic cancer. Neuron. 2026;114(2):250-267.e8.","journal-title":"Neuron"},{"issue":"13","key":"2667_CR331","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMra2302038","volume":"388","author":"CJ Haug","year":"2023","unstructured":"Haug CJ, Drazen JM. Artificial Intelligence and Machine Learning in Clinical Medicine, 2023. N Engl J Med. 2023;388(13):1201\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"2667_CR332","first-page":"5","volume":"1","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, et al. Med Research: Building Interdisciplinary Bridges and Leading Global Medical Innovation. Med Res. 2025;1(1):5\u20139.","journal-title":"Med Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02667-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:03:08Z","timestamp":1780632188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02667-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":332,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02667-w","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree on the publication of this research article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}